Floatz logo

Reboxetine

Cognitive Performance in Major Depression

Hadassah Medical OrganizationSmall moleculePhase 4 / ApprovedDormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

235 Active assets in the Cognitive Performance in Major Depression cohort.

Asset / SponsorPhaseRating
Risperdal
Johns Hopkins University
Phase 4BBB
Zelapar
Corium Innovations, Inc.
Phase 4BBB
S-Ketamine
Janssen Research & Development, LLC
Phase 4BBB
EDIVOXETINE
Eli Lilly and Company
Phase 3BBB
Opc-34712
Nova Scotia Health Authority
Phase 4BBB

View all 50 →

Same molecule, other indications

Reboxetine is also rated in:

PainDormant
B
Indicative ·
59 / 100
View asset →
stroke disorderDormant
B
Indicative ·
58 / 100
View asset →
depressive disorderDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →